Results 111 to 120 of about 8,737 (161)
Results from the Survey of Antibiotic Resistance (SOAR) 2018-21 in Türkiye: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. [PDF]
J Antimicrob ChemotherTorumkuney D +8 more
europepmc +1 more source
Results from the Survey of Antibiotic Resistance (SOAR) 2018-21 in Tunisia: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. [PDF]
J Antimicrob ChemotherTorumkuney D +5 more
europepmc +1 more source
Global concerns, local challenges: the alarming spread of FC428-related gonococcal strains in Nanchang City, 2021. [PDF]
BMC MicrobiolJiang Q +10 more
europepmc +1 more source
The World Health Organization (WHO) Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP) reports continuously high levels of ceftriaxone resistance across Viet Nam, 2024. [PDF]
Lancet Reg Health West PacLan PT +7 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
DICP, 1990
Cefixime is a new orally active third-generation cephalosporin with a broad spectrum of activity against a variety of both gram-positive and -negative bacteria including many beta-lactamase-producing strains of streptococci, Haemophilus influenzae, Neisseria gonorrhoeae, and the majority of the Enterobacteriaceae.
N J, Leggett, C, Caravaggio, M J, Rybak
openaire +2 more sources
Cefixime is a new orally active third-generation cephalosporin with a broad spectrum of activity against a variety of both gram-positive and -negative bacteria including many beta-lactamase-producing strains of streptococci, Haemophilus influenzae, Neisseria gonorrhoeae, and the majority of the Enterobacteriaceae.
N J, Leggett, C, Caravaggio, M J, Rybak
openaire +2 more sources